SII and Gates MRI Join Hands
Serum Institute Set to Manufacture Promising M72 TB Vaccine: The Serum Institute of India (SII) has entered into an agreement with the Gates Medical Research Institute (Gates MRI) to establish manufacturing capacity for the M72/AS01E tuberculosis vaccine candidate.
SII will manufacture and supply the vaccine at scale if the ongoing Phase III clinical trials demonstrate favourable results and the candidate receives the necessary regulatory approvals.
Focus on Global TB Prevention
The partnership aims to make a potential new TB vaccine available at affordable prices, particularly in countries carrying a high burden of tuberculosis.
Large-scale production by SII could improve vaccine accessibility for low- and middle-income countries and strengthen international efforts to reduce the global impact of TB.
Static GK fact: Tuberculosis is caused by the bacterium Mycobacterium tuberculosis and most commonly affects the lungs, where it is known as pulmonary tuberculosis.
Understanding M72/AS01E
M72/AS01E is an investigational vaccine candidate designed primarily to protect adults and adolescents against pulmonary TB. The candidate was originally developed by GlaxoSmithKline (GSK), with further development being undertaken by Gates MRI using technology licensed from GSK.
If successful and approved, M72/AS01E could become an important addition to the existing TB prevention toolkit.
The candidate is particularly significant because the currently available BCG vaccine has been used for more than a century and provides its strongest protection against severe forms of TB in young children.
Why Phase III Trials Matter
The agreement does not mean that M72/AS01E is already an approved vaccine. Its manufacturing and supply plans remain dependent on the successful completion of Phase III trials and subsequent regulatory clearances.
Phase III studies are conducted on large groups of participants to assess a vaccine’s efficacy, safety and overall benefit-risk profile before regulatory authorities consider approval.
Static GK Tip: BCG stands for Bacillus Calmette-Guérin. It remains the only widely used licensed vaccine against tuberculosis.
Serum Institute’s Global Role
The Serum Institute of India is one of the world’s largest vaccine manufacturers by volume and supplies vaccines to numerous countries.
Its manufacturing capabilities have supported immunisation programmes against diseases including polio, measles, meningitis and influenza, in addition to its major role in COVID-19 vaccine production.
The M72 partnership further highlights India’s importance in global vaccine manufacturing and public-health supply chains.
Significance for India and the World
The proposed manufacturing arrangement could combine Gates MRI’s vaccine-development expertise with SII’s large-scale production capabilities.
If the candidate proves successful, expanded manufacturing could help increase access to a potentially important new TB vaccine while supporting global efforts to reduce tuberculosis-related illness and deaths.
Static GK fact: The World Health Organization (WHO) launched the End TB Strategy, which seeks to end the global TB epidemic through major reductions in TB incidence and mortality.
Static Usthadian Current Affairs Table
Serum Institute Set to Manufacture Promising M72 TB Vaccine:
| Fact | Detail |
| Indian manufacturer | Serum Institute of India |
| Partner | Gates Medical Research Institute |
| Vaccine candidate | M72/AS01E |
| Target disease | Tuberculosis |
| Main target group | Adults and adolescents |
| Key target | Pulmonary tuberculosis |
| Trial stage | Phase III |
| Original developer | GlaxoSmithKline |
| Existing TB vaccine | BCG |
| Manufacturing condition | Successful trials and regulatory approvals |
| Major objective | Affordable large-scale access to a potential new TB vaccine |
